Cytokine Release Syndrome Clinical Trial
Official title:
Peri-operative Prediction of Prolonged Stay in the Cardiac Intensive Care Unit for Adult Cardiac Surgery With Cardiopulmonary Bypass
The purpose of this study is to create a model using intra-operative modified SOFA score and peri-operative clinical factors to predict prolonged stay in the cardiac intensive care unit (CICU) for adult cardiac surgery with heart-lung machine
Cardiac surgery using cardiopulmonary bypass (CPB) is commonly associated with a systemic inflammatory response that exacerbates peri-operative life-threatening complications and multiple organ dysfunction syndromes. These features can prolong the stay in the CICU. Many peri-operative clinical risk factors contribute to those adverse outcomes resulting in prolonged CICU stay. If the investigators can create a model to identify the effects of these intra-operative clinical risk factors to prolonged CICU stay ;
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03685383 -
Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation
|
N/A | |
Terminated |
NCT04540120 -
Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome
|
Phase 2 | |
Terminated |
NCT03557749 -
Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
|
||
Active, not recruiting |
NCT04150913 -
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
|
Phase 2 | |
Completed |
NCT04643678 -
Anakinra in the Management of COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04975555 -
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
|
Phase 2 | |
Terminated |
NCT04403685 -
Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers
|
Phase 3 | |
Completed |
NCT04366908 -
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
|
Phase 2 | |
Completed |
NCT05349669 -
Jafron Haemoadsorption During Cardiopulmonary Bypass
|
Phase 2 | |
Completed |
NCT04720378 -
Safety and Tolerability Study of IV ST266 in COVID-19 Subjects
|
Phase 1 | |
Terminated |
NCT04415073 -
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
|
Phase 2 | |
Completed |
NCT03533101 -
Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT04403061 -
Th1/Th2/Th17/TREG and TLRs Activation/KIR for COVID 19 Prediction of Outcome
|
||
Recruiting |
NCT05414162 -
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
|
||
Terminated |
NCT04377503 -
Tocilizumab Versus Methylprednisolone in the Cytokine Release Syndrome of Patients With COVID-19
|
Phase 2 | |
Completed |
NCT04475588 -
Efficacy and Safety of Itolizumab in COVID-19 Complications
|
Phase 2 | |
Recruiting |
NCT04781803 -
Cyclosporine on Day Zero as Prophylaxis for Cytokine Release Syndrome
|
Phase 2 | |
Completed |
NCT01353157 -
Study of the Clinical Scoring System and Cytokines for Prediction of Inflammatory Response in Major Surgery
|
N/A | |
Completed |
NCT04048525 -
Cytokine Removal With CVVHD Compared to CVVH
|
N/A | |
Recruiting |
NCT04048434 -
Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)
|
N/A |